% | $
Quotes you view appear here for quick access.

Catalyst Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • staccani staccani Nov 5, 2012 3:26 PM Flag

    CPRX valuation by BioMarin. from $1.2B to $4.1B

    trd4profit, this is an acquisition in cash AND licencing rights. The biggest part of the priice paid to CPRX is the licencing rights of Fidarpse for exclusive commercialization in NAM. CPRX values the revenue potential at $50M from Fidarpse in NAM. Normally Pharma companies are valued at 4 times their annual revenue, hence the maths above.

    Sentiment: Strong Buy

0.794-0.086(-9.77%)Jun 24 4:00 PMEDT